Jun 27, 2025, 13:37

2025 LCRF – Boehringer Ingelheim Early Investigator Award on Innovative Approaches Toward the Treatment of HER2-Driven Lung Cancer

This award supports early-career investigators pursuing transformative research into HER2-mutant non-small cell lung cancer (NSCLC), from uncovering oncogenic biology to developing novel therapeutics and predictive biomarkers.

Eligibility Criteria

Investigator teams must include studies in patients with HER2-mutant lung cancer
Early-stage investigators at academic, clinical, or non-profit institutions
Research topics may include (but aren’t limited to):
- Biology and mechanisms of HER2-driven tumor progression
- Real-world data analyses in HER2-mutant NSCLC
- Primary or secondary resistance mechanisms to targeted, immune, or combination therapies
- Tumor microenvironment and immune landscape studies
- Biomarker identification for predicting treatment sensitivity
- Strategies to optimize efficacy and tolerability of HER2-targeted treatments

Funding Details

Up to 250,000 USD total budget
Funding period: 2 years
Single LCRF application allowed per investigator per cycle

Key Deadlines

LOI Due: July 29, 2025
Full Proposal Invitations: Following LOI review
Full Proposal Due: October 7, 2025
Award Notifications & Start Date: See full RFP

Where to Apply & More Information

Submit your LOI via the LCRF Grant Application Portal
Full RFP and application instructions: visit LCRF’s website or contact [email protected]

biomarkers Boehringer Ingelheim cancer early investigator HER2 LCRF Lung cancer NSCLC OncoDaily Oncology real world data Resistance mechanisms targeted therapy tumor microenvironment

King Albert II’s Brave Battle: A Decade of Fighting Skin Cancer

25 Posts Not To Miss From ESMO GI 2025

Botensilimab and Balstilimab Show Durable Survival in MSS Colorectal Cancer: ESMO GI 2025 Update

Julian McMahon Dies at 56: A Look Back at His Private Cancer Battle and Legendary Acting Career

Vivek Subbiah: It’s Time We Evolve WHO Cancer Classification